Design of viral dynamic studies for efficiently assessing potency of anti-HIV therapies in AIDS clinical trials

Biometrical Journal

Volumn 44, Issue 2, 2002, Pages 175-196

  Wu, Hulin ^a   Ding, A Adam ^b  

^a FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

AIDS; Asymptotic relative efficiency; Clinical trial simulation; Design of experiment; HIV; Optimal design; Surrogate marker; Viral dynamics

Indexed keywords

CLINICAL RESEARCH; DYNAMICS; EFFICIENCY; INTELLIGENT SYSTEMS; MEDICAL APPLICATIONS; MONTE CARLO METHODS;

AIDS; AIDS CLINICAL TRIAL; ASYMPTOTIC RELATIVE EFFICIENCY; CLINICAL TRIAL; CLINICAL TRIAL SIMULATION; HIV; HIV DYNAMICS; OPTIMAL DESIGN; SURROGATE MARKER; VIRAL DYNAMIC;

DESIGN OF EXPERIMENTS;

EID: 0036005372     PISSN: 03233847     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4036(200203)44:2<175::AID-BIMJ175>3.0.CO;2-3     Document Type: Article

References (34)

1. Optimum experimental designs for properties of a compartmental model
2. Optimal Bayesian design applied to logistic regression experiments
3. Relationships between antiviral treatment effects and biphasic viral decay rates in modeling HIV dynamics
4. A comparison study of models and fitting procedures for biphasic viral dynamics in HIV-1 infected patients treated with antiviral therapies
5. Assessing antiviral potency of anti-HIV therapies in wvo by comparing viral decay rates in viral dynamic models
6. Optimized blood sampling protocols and sequential design of kinetic experiments
7. Efficacy of drug combination and dosing regimen in antiviral therapy
8. Viral dynamics in vivo: Limitations on estimates of intracellular delay and virus decay
9. Novel approaches for the evaluation of new drugs: Approaches using viral dynamics
10. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
11. Dynamics of HIV-1 replication in vertically-infected infants
12. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion
13. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection
14. Optimal design in random-effects regression models
15. Influence of delayed viral production on viral dynamics in HIV-1 infected patients
16. Individual prognoses of long-term responses to antiretroviral treatment based on virological, immunological and pharmacological parameters measured during the first week under therapy
17. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study
18. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression of AIDS
19. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time
20. Decay characteristics of HIV-1-infected compartments during combination therapy
21. Robust experiment design via maximin optimization
22. Viral dynamics in human immunodeficiency virus type 1 infection
23. Linear rank tests under general alternatives, with application to summary statistics computed from repeated measures data
24. Interpatient variation of viral dynamics in HIV-1 infection: Modeling results of AIDS Clinical Trials Group Protocol 315
25. Estimation of HIV dynamic parameters
26. Population HIV-1 dynamics in vivo: Applicable models and inferential tools for virological data from AIDS clinical trials
27. Characterization of viral dynamics in HIV-1-infected patients treated with combination antiretroviral therapy: Relationships to host factors, cellular restoration and virological endpoints
28. Inappropriate model-fitting methods may lead to significant underestimates of viral decay rates in HIV dynamic studies